Objective: To assess the relationship between allergic rhinitis and allergic conjunctivitis and to assess the role of Intranasal corticosteroid in the management of Allergic rhinoconjunctivitis.

Material and methods: The study was done in Ananta Institute of medical Sciences, Rajsamand, Rajasthan from February 2016 to October 2017. A total of 100 patients with the diagnosis of allergic rhinitis or allergic conjunctivitis attended ENT or Ophthalmology outpatient department were included in our study. Type I allergy was tested by a specific IgE antibody test in the blood. iTNSS (instantaneous total nasal symptom score), iTOSS (instantaneous total ocular symptom score), rTNSS(reflective total nasal symptom score) and  rTOSS (reflective total ocular symptom score) were noted before as well as after 1 week treatment with intranasal steroid spray Fluticasone Furoate(FF).

Results: A total of 100 patients were included in our study out of which 47 were male and 53 were female. Age of the patients ranges from 20 to 60 years with the mean age of 34.8 years.

79% cases included in present study were having symptoms of rhinoconjunctivitis; 13% cases were having only rhinitis symptoms and rests 8% were having only conjunctivitis symptoms.

The mean pre treatment iTNSS and iTOSS scores were 4.45±2.70 and 2.35±1.45 respectively, similarly, the mean post treatment iNSS and iTOSS were 2.36±1.74 and 1.16±1.43 respectively.

Conclusion: eye symptoms frequently occur in allergic rhinitis and the mechanism behind this can be explained by a neural mechanism i.e. nasal–ocular reflex. Intranasal steroid like Fluticasone Furoate with high topical potency and low potential for systemic effects is a good candidate for rhinitis treatment as well to manage ocular symptoms